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Abstract 
Importance: There is a paucity of data on the changes in geography and ethnicity of patients on 
the key trials used by the FDA for establishing dosing, safety, and efficacy. 
Objective:  To describe the globalization and racial composition of regulatory data from FDA 
approved medications. 
Design, Setting, and Participants: A descriptive analysis of 171 pivotal trials from 70 FDA new 
molecular entities, new combinations, and biologics approved by the Unites States Food and 
Drug Administration which captured racial data for 126,342 participants from the years 1997, 
2004, 2009 and 2012 in the clinical areas of cardiovascular disease, central nervous system, and 
oncology. 
Main Outcome(s) and Measure(s): The number of and the specific countries that hosted a 
clinical investigator site that contributed participants to the pivotal clinical trial. Also, the 
percentage of participants from reported racial groups of White, Black, Asian, or other in these 
pivotal trials.  
Results: The total number of unique countries was 31 in 1997, 43 in 2004, 56 in 2009, and 61 in 
2012. The mean number of countries involved per trial was 3.6 in 1997, to 4.4 in 2004, 8.3 in 
2009, and 15.0 in 2012.  
The percentage of patients identified as Caucasians was 91.0% in 1997, 90.6% in 2004, 87.1% in 
2009, and 81.1% in 2012, all at rates higher than that of the American population11.  The yearly 
percentage of black participants on pivotal trials ranged from 2.9% - 6.9% over the study period. 
Asian participants were 0.1% of total patients in 1997, but had risen to 10.8% of patients in 
2012. 
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A group of 29 countries mostly from North America and Western Europe represented “classic 
countries” and hosted investigator sites in all fours years evaluated. Countries in the regions of 
Asia, Eastern Europe, and South America were not well represented on pivotal trials in the early 
years evaluated, but have since increased in representation. 
Conclusions and Relevance: This analysis shows a doubling of the number of countries involved 
in pivotal trials and a quadrupling of the number of countries per individual trial over a 15-year 
period. This substantiates the notion that pivotal trial programs have become more global. 
Despite an increase in globalization, the vast majority (>80%) of patients on pivotal clinical trials 
are white. These patients are now enrolled in Eastern Europe and South America in addition to 
the longstanding contributors from North America and Western Europe. This allows for greater 
confidence in the ability to determine efficacy and detect risk in white populations, but do not 
provide the same level of ascertainment in non-white groups. 
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Introduction 
The development of safe and effective medication has been a vital tool in improving the quality 
and length of human lives across the globe. Indeed, access to medication is recognized as a 
human right  by the World Health Organization1.  In the United States the use of prescription 
drugs is widespread, with 47.9% of the population using at least one prescription drug in the 
past month2. 
The FDA Center for Drug Evaluation and Research (CDER) is charged with ensuring the safety 
and efficacy of drugs for use among the entire US citizenry. This includes the diversity of 
populations within the USA  and moreover, CDER’s scope has expanded as other regulatory 
bodies use FDA decisions as part of their own domestic policy.3 The FDA’s position as a global 
regulatory agency is relevant as biopharmaceutical clinical trials are being conducted in many 
regions of the globe,4 including Eastern Europe, Latin America, and Asia5. Data from 300 clinical 
trials published in three major medical journals reveal that the number of countries hosting 
clinical trials has more than doubled between 1995 and 2005; with at least one third of major 
industry sponsored phase III trials having been conducted completely outside of the United 
States6. However, there is a paucity of data on the changes in the geography and ethnicity of 
patients on the key trials used by the FDA for establishing dosing, safety, and efficacy. 
When assessing data from across the world, regulatory bodies consider intrinsic and extrinsic 
factors that may influence foreign clinical data and the ability of regulatory agencies to 
extrapolate the data to domestic populations. Intrinsic ethnic factors are genetic and physiologic 
in nature, such as race and genetic polymorphisms, while extrinsic ethic factors are associated 
with environment and culture5,7,8. Both intrinsic and extrinsic ethnic factors contribute to the 
decision to require a “bridging study” to allow extrapolation of the data to different regions7. 
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Additionally, because of the documented differences in drug response across geographical 
regions9, it is of value to assess where the pivotal trials we use to guide drug approvals and 
ultimately drug utilization are being conducted. 
 A key part of the safety and efficacy assessment are the “Pivotal Trials.” These are typically 
large randomized controlled phase III trials from which is derived the basis for the labeled 
indication and approved dosages, as well as the adverse drug reaction profile. Due to their 
importance in the regulatory decision, these pivotal trials represent a major focus of FDA 
medical review and are subject to a significant degree of scrutiny. Additionally, payers use the 
data generated from these trials in determining initial coverage decisions and medical 
associations also use these data to generate clinical practice guidelines.  
To answer the questions about the globalization and ethnic composition of regulatory data, a 
review of the pivotal trials was conducted in FDA approvals from the years 1997, 2004, 2009 and 
2012 in the clinical areas of cardiovascular disease, central nervous system, and oncology. The 
focus is on identifying the changes in the countries that are a part of the pivotal trial landscape 
and on the ethnic composition of the patients in the trials. 
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Methods 
Source of data 
The lists of approvals by year and within specific clinical areas were obtained via 
CenterWatch.org. The identified approvals within the clinical areas and associated time period 
were then confirmed through the FDA registry’s Drugs@FDA month-by-month approvals. 
In order to identify the pivotal trials, section 14 (Clinical Studies) of the original FDA Approval 
Label for each drug was used. The studies in this section provide the primary support of 
efficacy10. The pivotal trials were confirmed in the publicly available FDA medical reviews 
available online at Drugs@FDA, and revised when the FDA Medical Review explicitly identified 
specific trials as pivotal (for inclusion) or supportive (for omission). After these trials were 
confirmed, the medical reviews served as the initial sources of data on the countries of clinical 
investigator sites and on the racial demographics of the trial participants. Once collected, these 
data were supplemented by the primary published literature on the relevant trial, which were 
obtained through PubMed searches. The results were compiled into a Microsoft Excel® database 
for descriptive analysis. The investigators chose to focus on the clinical areas of cardiovascular, 
central nervous system (CNS), and oncology, as they represent diverse disease conditions, have 
a large volume of patients, and have multiple drug approvals in each of the years under 
assessment. 
Inclusion 
All approvals that were granted by the FDA within the years of interest in the clinical areas of 
CNS, CV, and oncology were included in this study. The FDA classifies their New Drug 
Applications (NDAs) by chemical type and, for the purposes of this study, we included chemical 
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types 1 (New Molecular Entity) and 4 (New combination) as well as Biologic Applications (BLAs). 
These approvals are more likely to rely on a more rigorous pivotal trial as compared to other 
chemical types for a new active ingredient (type 2), new dosage form (type 3), etc. There were 
from 17 approvals (5 CNS, 6 CV, and 6 oncology) and 65 pivotal trials in 1997, 17 approvals (6 
CNS, 4 CV, and 7 oncology) with 44 trials in 2004, 17 (3 CNS, 9 CV, and 5 oncology) approvals 
with 38 trials in 2009, and 2012 included 19 total approvals (3 CNS, 4 CV, and 12 oncology) with 
24 trials. Ethnic data was not available for two approvals (one approval with two trials in 1997 
and one approval with one trial in 2004) as so approvals are not represented in Table 1. Ethnic 
data was not available for twelve trials in 1997, nine trials from 2004, and one trial from 2009. 
Country data was not available for two trials from 1997. 
Definitions of Race and How Data Were Collected 
The FDA follows the DHHS Office of Management and Budget recommendation for standard 
ethnicity categories. However, to account for expected variability in racial reporting, all 
information was collected as it was presented in its most detailed form. This resulted in the 
utilization of the following racial categories: Caucasian, Black, Asian, Hispanic/Latino, Native 
American, Pacific Islander, and other. In some cases, these data were presented as 
Caucasian/white or non-Caucasian/non-white. Hence, a new category called “Non-white 
unspecified” was created. If racial data had been reported as unknown, it was recorded as such. 
The reporting of Hispanic/Latino in medical reviews and primary publications was the least 
standardized because this term is largely an American construct. The difficulty of applying the 
Hispanic/Latino label outside of the USA prohibits its applicability globally and thus 
Hispanic/Latino data was combined with the Caucasian/white group. 
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A World Map (Figure 3) provides a snapshot of the global involvement in pivotal trials. The 
regional breakdown used is modified from the regional groups of the United Nations General 
Assembly 
(http://www.un.int/wcm/webdav/site/gmun/shared/documents/GA_regionalgrps_Web.pdf).  
Reporting of Race 
Racial information was obtained through the above methods for 87.1% of all 171 pivotal trials 
evaluated including 81.5% of the pivotal trials in 1997, 79.5% in 2004, 97.4% in 2009, and 100% 
in 2012. Within clinical areas obtainment rates were at 97.9%, 80.9%, and 87.5% for CNS, CV, 
and oncology respectively. Racial data was less consistently reported for oncology in 1997 with 
only data for 9 of 18 pivotal trials being obtained through the primary literature and FDA 
medical review. 
A survey of the reporting of racial information from the pivotal trials on FDA approved labeling 
was also conducted to assess the extent to which this information has been disseminated to the 
general public.  
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Results 
Number of patients 
The assessment included a total of 70 FDA approvals (68 with racial data) and provided racial 
data on a total of 126,342 participants from 171 pivotal trials (149 with racial data) across the 
four years and three clinical areas (Table 1). Trials in the cardiovascular disease area enrolled the 
most patients, representing 70.7% of all participants evaluated. The majority of evaluated years 
were included over 30,000 participants with the exception of 2004, which, despite having an 
equivalent number of approvals, included only 14,980 patients on pivotal trials. 
Global Participation 
One of the major aims of this study is to provide an assessment of trends in the globalization of 
pivotal trials. To that point the total number of unique countries who hosted an investigator site 
that recruited patients for a pivotal trial in any of the three clinical areas increased across the 
time period from 31 in 1997, to 43 in 2004, 56 in 2009, and finally 61 countries in 2012 (Figure 
1). The mean number of countries involved per trial accordingly increased from 3.6 in 1997, to 
4.4 in 2004, 8.3 in 2009, and then 15.0  in 2012 (Figure 2). The mean number of countries per 
approval was from 9.1 in 1997, 9.0 in 2004, 14.4 in 2009, and 17.3 in 2012. 
In the CNS area, the total number of unique countries hosting investigator sites across the time 
period was 23 in 1997, 28 in 2004, 17 in 2009, and 46 countries in 2012 (Figure 2). The mean 
number of countries involved per trial was 3.2 in 1997, 3.0 in 2004, 3.7 in 2009, and 15.3 in 2012 
(Figure 2). The mean number of countries involved per approval was 9.6 in 1997, 7.2 in 2004, 7.0 
in 2009, and 22.8 per approval in 2012 (Figure 2). 
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In the CV area, the total number of unique countries hosting investigator sites across the time 
period was 19 in 1997, 30 in 2004, 53 in 2009, and 40 in 2012 (Figure 2). The mean number of 
countries involved per trial was 3.5 in 1997, 4.9 in 2004, 10.1 in 2009, and 12.4 countries per 
trial in 2012 (Figure 2). The mean number of countries involved per approval was 9.7 in 1997, 
14.0 in 2004, 18.2 in 2009, and 16.4 in 2012 (Figure 2). 
In the oncology area, the total number of countries hosting investigator sites across the time 
period was 28 unique countries in 1997, 33 in 2004, 34 in 2009, and 56 in 2012 (Figure 1). This 
growth in the globalization of oncology trials is consistent with the trend in mean number of 
countries involved per trial, which corresponds to 4.0 countries in 1997, 7.1 countries in 2004, 
8.9 countries in 2009, and 15.8 countries per trial in 2012 (Figure 2). The mean number of 
countries involved per approval was 8.2 in 1997, 7.7 in 2004, 12.0 in 2009, and 16.4 in 2012 
(Figure 2). 
Patient Ethnicity/Race 
The percentage of patients who were identified as Caucasians was 91.0% in 1997, 90.6% in 
2004, 87.1% in 2009, and 81.1% in 2012 (Table 2). Additionally, the range of Caucasian 
percentage in the clinical trials was 20.7% - 100% in 1997, 75.4% - 100% in 2004, 35.1% - 100% 
in 2009, and 47.9% - 98.1% in 2012. The percentage of pivotal clinical trial participants that were 
Caucasians was higher than that of the American population11 in each of the evaluated years.   
The yearly percentage of black participants on pivotal trials was 2.9% - 6.9% over the study 
period, consistent with the lower participations rates that have been previously reported12,13.  
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Asian participants have seen an increase in representation. Over the study period Asian 
participants were 0.1% of total patients in 1997, but had risen to represent 10.8% of patients in 
2012. 
World Maps 
A group of 29 countries, representing the “classic countries” involved in the landscape of pivotal 
trials, hosted investigator sites in all four of the years evaluated. Western Europe and all of the 
North American weigh prominently within this group. Seventeen of the nineteen Western 
European countries that hosted an investigator site in any of our four years of interest are a part 
of this group and eight of them (Belgium, France, Germany, Italy, Netherlands, Spain, Sweden, 
and the UK) were in the top ten most represented countries in at least two of the four years. 
Three other “classic countries” were in the top ten in two or more years and those were 
Australia (2004 and 2012), Canada (all four years), and the United States (all four years). Outside 
of Western Europe and North America, the “classic countries” are made up of Croatia, Czech 
Republic, Poland, and Russia from Eastern Europe, Australia and New Zealand, South Africa from 
Africa and Argentina from South America. No Asian countries hosted investigator sites in all four 
time periods 
Eastern Europe can also be classified as an emerging region. There are five “classic countries” 
(Croatia, Czech Republic, Hungary, Poland, and Russia) from Eastern Europe that participated in 
a trial in each year evaluated. However, Croatia contributed to less than 5% of the total pivotal 
trials in each year. Eastern European involvement grew from seven countries on trials in 1997, 
to eight in 2004, thirteen in 2009, and to sixteen in 2012.  
Asia was not well represented on pivotal trials in 1997. In 2004, India, Malaysia, Singapore, and 
Thailand hosted investigator sites for pivotal trials along with Hong Kong* and Taiwan*, for a 
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total of six countries/territories. In 2009, the number increased to eleven with the addition of 
mainland China, Japan, Pakistan, and South Korea and eleven again in 2012 with the addition of 
Saudi Arabia and the loss of Pakistan. Also notable within the Asian region is the rapid rise to 
prominence of China, India, and South Korea, each of which were present on over 25% of trials 
in 2012. 
Like Asia, South America was not well represented in 1997. Argentina, the only “classic county” 
from the region was the only country to contribute patients to a pivotal trial in 1997. Brazil, 
Chile, Peru, and Venezuela joined in 2004 to bring the total to five countries. In 2009, Ecuador 
hosted a site to bring the total to six countries, finally in 2012, Colombia, Costa Rica, and 
Guatemala hosted sites while Venezuela did not, which increased the total number of 
participating countries to eight. Argentina, Brazil, and Chile were present in greater than one 
third of trials in 2012.   
Separate Clinical Areas Ethnicity/Race 
The racial composition of the CNS approvals had a similar trend to what was seen in the overall 
results. The data (Table 2) show an excess of Caucasians, fewer blacks, and growth in Asian 
patient participation with the exception of 2009. In 2009, two of the three CNS approvals had 
over 30% black participants in the trials. 
The vast majority of CV pivotal trial patients were Caucasian, although there was a decline in 
participation from 91.9% in 1997 to 80.6% in 2012. Overall, the percentage of black participants 
on trials in the CV area does not appear to have changed by a large degree over this time span 
from 3.1% in 1997, 4.1% in 2004, 4.9% in 2009, to 4.2% in 2012. However, there were trials in 
which black participants were a 46.7-79.3% of the population.  
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Of oncology approvals, 1997 represented the year that included the lowest percentage of 
Caucasian participants at 79.4%, while 18.7% of the non-Caucasian data was reported as simply 
not Caucasian. After 1997, the percentage of Caucasians peaked in 2009 at 87.2% while recent 
2012 data reports Caucasians at 80.6%. The enrollment of black participants remained low 
across the timeframe while the increase of Asian participation in oncology trials increased from 
0.4% in 1997 to 11.4% in 2012 (Table 2). 
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Discussion 
This analysis shows a doubling of the number of countries involved in pivotal trials and a 
quadrupling of the number of countries per individual trial over a 15-year period. This 
substantiates the notion that pivotal trial programs have become more global. The globalization 
of pivotal trials supports the FDA’s position as a global regulatory agency with the capability and 
responsibility to collect and analyze data from diverse populations across various countries. One 
influence of this trend toward globalization is the increased standardization of clinical trial 
protocols, clinical site quality, data collection and data submission, so as to meet the 
requirements for inclusion in FDA evaluated pivotal trial data. As pivotal trials have become 
more globalized, the FDA and other regulatory partners can now assess the efficacy and safety 
of medications holistically for final approval, and also use the data to support the efficacy and 
safety within specific countries or regions. 
Despite an increase in globalization, the vast majority (>80%) of patients on pivotal clinical trials 
are white. These patients are now enrolled in Eastern Europe and South America in addition to 
the longstanding contributors from North America and Western Europe. This allows for greater 
confidence in the ability to determine efficacy and detect risk in white populations, but do not 
provide the same level of ascertainment in non-white groups. As non-white patients make up 
22.1% of USA population and, according to the US Census Bureau Population Projections are 
expected to increase to 26.3% by 2035, and 31.1% by 2060, there is a need for more inclusive 
clinical trial planning to assure drug safety across patients of all ethnicities.  
Insufficient data does not guarantee harm but do provide a basis for the delayed detection and 
dissemination of risk in underrepresented populations. Serious but uncommon risks are 
detected through post-marketing pharmacovigilance programs, such the FDA’s MedWatch 
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program, as soon as the medication is used by a large enough population for such risks to 
emerge. With increased representation of previously underrepresented populations on future 
pivotal trials, these risks are more likely to be detected before the medication is approved for 
use in the general population. This should result in more accurate and targeted warnings and 
precautions, which improves safety and efficacy. 
Aligned with the importance of the influence of race on drug efficacy and safety, the reporting 
of the demographic composition of the trials to the public is a robust way to disseminate this 
information. Regular reporting allows health care providers and patients to assess if the 
population studied matches the individual for which the drug may be prescribed. However, the 
use of the OMB categories is not sufficient for the global environment. The increased reporting 
of the racial data is reflective of the increased influence of its growing relevance in the public 
discourse. Racial data for approvals in the oncology and CV areas have been well-reported in the 
more recent time frame and it is important that this upward trend continues along with an 
increased assessment on differences in efficacy and safety between groups.  
Future Directions 
Because of the significant time gap between regulatory approval and pivotal study recruitment, 
even the 2012 data reflects trials that began in the previous decade. An “advanced search” of 
ClinicalTrials.gov for all open, interventional, phase III, industry sponsored trials reveals that 
North America is a host for 51.4% of the 2,331 total ongoing studies. This may mean that in the 
future trials will become even more globalized and that the United States will serve as a host for 
fewer pivotal trials. In order to be equipped to handle for the current and growing globalization 
tools for ethnobridging should be further refined and utilized. 
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Furthermore, in order to optimally approve medications for an increasingly diverse American 
and global population, pivotal trials should be altered. Ideally, pivotal trials will be populated 
well-enough to allow regulators to make definitive safety and efficacy decisions for people in all 
possible racial groups and ethnicities. This would, in turn, impact who is recruited in pivotal 
trials and where these trials occur. Additionally, improvements to the trial evaluation methods 
should be implemented. One such tool is the use of ethnobridging to allow regulators to make 
assessments to shorten risk signal detection time and to more quickly disseminate safety 
information in underrepresented trial participants. 
Summary 
As the drug development enterprise becomes a more global institution, the role of the United 
States Food and Drug Administration is expanding outside of the borders of the United States as 
it becomes a global regulatory agency. The number of countries hosting investigator sites has 
nearly doubled over the course of fifteen years between 1997 and 2012 while the number of 
countries per approval has also doubled and the number of countries per pivotal trial has 
quadrupled. The population which was previously dominated by Caucasians from North America 
and Western Europe has expanded into Asia, Eastern Europe, and South America but has still 
remained predominantly Caucasian. The new picture of the pivotal trial landscape underscores 
the importance of the development and utilization of ethnobridging tools to improve risk 
detection. These tools can also serve to improve the efficacy and safety of medicine for or an 
ethnically diverse global population. 
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Figures and Tables 
Table 1. Total Number of Patients and Pivotal Trials Assessed by Racial Demographics 
 1997 2004 2009 2012 TOTAL 
 Participants Trials Participants Trials Participants Trials Participants Trials Participants Trials 
CNS 6,929 19 6,847 22 5,189 9 3,810 6 22,775 56 
CV 28,031 25 5,360 6 35,811 21 20,066 5 89,268 57 
Oncology 3,316 9 2,773 7 1,310 7 6,883 13 14,282 36 
TOTAL 38,293 53 14,980 35 42,310 37 30,759 24 126,342 149 
 
Figure 1. Total Number of Countries Hosting Investigator Sites per Year
 
Figure 1a. All Clinical Areas 
 
Figure 1b. Separate Clinical Areas 
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Figure 2. Number of Countries Hosting Investigator Sites per Pivotal Trial 
Figure 2a. All Clinical Areas 
Figure 2b. Individual Clinical Areas 
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Table 2. Racial Composition of Pivotal Trials  
Year White Black Asian Other (or 
unspecified) 
COMBINED 
 % Total Range % Total Range % Total Range % Total Range 
1997 91.0 20.7 – 100 2.9 0 – 70.3 0.1 0 – 4.5 5.9 n/a 
2004 90.6 75.4 – 100 5.4 0 – 20.0 1.5 0 – 12.4 2.5 n/a 
2009 87.1 35.1 – 100 6.9 0 – 50.4 4.2 0 – 23.5 1.8 n/a 
2012 81.1 47.9 – 99.0 3.8 0 – 46.7 10.8 0 – 34.6 2.3 n/a 
         
CNS         
 % Total Range % Total Range % Total Range % Total Range 
1997 93.3 74.8 – 100 2.9 0 – 22.2 0.3 0 –  2.1 3.5 n/a 
2004 92.1 75.4 – 100 6.3 0 – 20.0 0.6 0 – 4.6 0.9 n/a 
2009 69.2 35.1 – 100 22.1 3.2 – 50.4 4.6 0.6 – 21.7 4.1 n/a 
2012 84.5 65.0 – 100 1.7 0 – 7.0 11.9 0 – 34.6 1.9 n/a 
         
CV         
 % Total Range % Total Range % Total Range % Total Range 
1997 91.9 20.7 – 100 3.1 0 – 79.3 0.1 1.0 – 4.5 5.0 n/a 
2004 90.3 79.9 – 100 4.1 0 – 13.6 0.8 0 – 2.1 4.8 n/a 
2009 89.7 71.6 – 100 4.9 0 – 17.1 4.0 0 – 23.5 1.5 n/a 
2012 80.6 47.8 – 100 4.2 0 – 46.7 10.4 0 – 11.1 1.8 n/a 
         
ONCOLOGY         
 % Total Range % Total Range % Total Range % Total Range 
1997 79.4 70.1 – 100 1.1 0 – 16.9 0.2 0 – 3.2 19.3 n/a 
2004 87.3 77.6 – 100 5.6 0.2 – 12.2 5.2 0 – 12.4 2.0 n/a 
2009 87.9 77.5 – 100 3.1 0 – 21.1 7.2 0 – 13.6 1.8 n/a 
2012 80.6 59.4 – 100 4.0 0 – 23.5 11.4 0 – 32.3 3.9 n/a 
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Figure 3. World Map of Pivotal Trial Distribution 
 
Country Region 1997 2004 2009 2012 Categorization 
Morocco Africa 0.00 0.00 2.63 0.00 2009 only 
South Africa Africa 7.94 9.09 15.79 33.33 All years 
Tunisia Africa 0.00 0.00 5.26 4.17 2009 and 2012 
       
China Asia 0.00 0.00 5.26 25.00 2009 and 2012 
Hong Kong* Asia 0.00 4.55 7.89 12.50 2004 and on 
India Asia 0.00 2.27 18.42 37.50 2004 and on 
Japan Asia 0.00 0.00 2.63 16.67 2009 and 2012 
Malaysia Asia 0.00 2.27 5.26 8.33 2004 and on 
Pakistan Asia 0.00 2.27 2.63 0.00 2009 only 
Philippines Asia 0.00 0.00 7.89 16.67 2009 and 2012 
Saudi Arabia Asia 0.00 0.00 0.00 4.17 2012 only 
Singapore Asia 0.00 4.55 2.63 20.83 2004 and on 
South Korea Asia 0.00 0.00 10.53 33.33 2009 and 2012 
Taiwan* Asia 0.00 4.55 2.63 16.67 2004 and on 
Thailand Asia 0.00 2.27 5.26 12.50 2004 and on 
       
Australia Australia 7.94 15.91 21.05 45.83 All years 
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New Zealand Australia 4.76 9.09 10.53 4.17 All years 
       
Belarus Eastern Europe 0.00 0.00 0.00 8.33 2012 only 
Bulgaria Eastern Europe 0.00 2.27 7.89 12.50 2004 and on 
Croatia Eastern Europe 1.59 2.27 2.63 4.17 All years 
Czech Republic Eastern Europe 3.17 4.55 21.05 25.00 All years 
Estonia Eastern Europe 1.59 0.00 5.26 16.67 All but 2004 
Georgia Eastern Europe 0.00 0.00 2.63 0.00 2009 only 
Hungary Eastern Europe 6.35 4.55 15.79 25.00 All years 
Latvia Eastern Europe 1.59 0.00 5.26 8.33 All but 2004 
Lithuania Eastern Europe 0.00 0.00 7.89 8.33 2009 and 2012 
Macedonia Eastern Europe 0.00 0.00 0.00 4.17 2012 only 
Poland Eastern Europe 1.59 13.64 34.21 54.17 All years 
Romania Eastern Europe 0.00 2.27 7.89 25.00 2004 and on 
Russia Eastern Europe 3.17 4.55 31.58 45.83 All years 
Serbia Eastern Europe 0.00 0.00 0.00 4.17 2012 only 
Slovakia Eastern Europe 0.00 4.55 7.89 8.33 2004 and on 
Slovenia Eastern Europe 0.00 0.00 0.00 4.17 2012 only 
Ukraine Eastern Europe 0.00 0.00 10.53 25.00 2009 and 2012 
       
Austria Western Europe 12.70 11.36 13.16 37.50 All years 
Belgium Western Europe 20.63 18.18 23.68 33.33 All years 
Denmark Western Europe 6.35 6.82 26.32 16.67 All years 
Finland Western Europe 7.94 6.82 15.79 25.00 All years 
France Western Europe 20.63 18.18 26.32 62.50 All years 
Germany Western Europe 23.81 20.45 39.47 75.00 All years 
Greece Western Europe 1.59 4.55 5.26 20.83 All years 
Iceland Western Europe 0.00 0.00 2.63 0.00 2009 only 
Ireland Western Europe 7.94 4.55 5.26 4.17 All years 
Israel Western Europe 4.76 9.09 15.79 16.67 All years 
Italy Western Europe 12.70 13.64 34.21 70.83 All years 
Netherlands Western Europe 22.22 15.91 28.95 41.67 All years 
Norway Western Europe 3.17 6.82 18.42 16.67 All years 
Portugal Western Europe 3.17 4.55 7.89 16.67 All years 
Spain Western Europe 9.52 15.91 28.95 50.00 All years 
Sweden Western Europe 15.87 18.18 26.32 37.50 All years 
Switzerland Western Europe 7.94 13.64 7.89 12.50 All years 
Turkey Western Europe 0.00 6.82 7.89 20.83 2004 and on 
UK Western Europe 28.57 22.73 44.74 58.33 All years 
       
Canada! North America 30.16 18.18 36.84 54.17 All years 
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Mexico@ North America 1.59 4.55 5.26 20.83 All years 
USA$ North America 71.43 77.27 73.68 91.67 All years 
       
Argentina South America 1.59 4.55 18.42 33.33 All years 
Brazil South America 0.00 9.09 10.53 41.67 2004 and on 
Chile South America 0.00 4.55 7.89 37.50 2004 and on 
Colombia South America 0.00 0.00 0.00 8.33 2012 only 
Costa Rica South America 0.00 0.00 0.00 4.17 2012 only 
Ecuador South America 0.00 0.00 2.63 4.17 2009 and 2012 
Guatemala South America 0.00 0.00 0.00 4.17 2012 only 
Peru South America 0.00 2.27 2.63 12.50 2004 and on 
Venezuela South America 0.00 2.27 2.63 0.00 2004 and 2009 
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Figure Legend 
 Table 1.  
o Title - Total Number of Patients and Pivotal Trials Assessed by Racial 
Demographics 
o Caption - Number of participants from pivotal trials with available racial data 
that were included within the corresponding category. 
  
 Figure 1. 
o Title - Number of Countries Hosting Investigator Sites per Pivotal Trial 
o Caption -  a) All clinical areas b) Individual clinical areas 
 
 Figure 2. 
o Title - Number of Countries Hosting Investigator Sites per Pivotal Trial 
o Caption -  a) All clinical areas b) Individual clinical areas 
 
 Table 2.  
o Title - Racial Composition of Pivotal Trials 
o Caption - Percentage of total patients from all included pivotal trials within year 
and clinical area that were White, Black, Asian, or Other (or unspecified). And 
range of percentage of racial composition within year and clinical area. 
 
 Figure 3.  
o Title - World Map of Pivotal Trial Distribution 
o Caption – World map detailing changes in global pivotal trial distribution over 
15-year period. Numbers are the percentage of pivotal trials within the given 
year that included a clinical investigator site in country. 
o Footnotes : 
 * Hong Kong and Taiwan - grouped separate from China if reported as 
such in original data 
 ! Canada – considered in the “Western Europe and Other state” per UN 
 @ Mexico – considered “Latin American and Caribbean state” per UN 
 $ USA – not a member of any UN regional group 
 
